Sep 2026· International Journal of Laboratory Hematology· 0 citations· 61 references
Medicine
TL;DR
This document provides updated guidance on the examination and reporting of BM specimens and is an extension and refinement of the 2008 ICSH guidelines, whereby findings from all diagnostic modalities are synthesized within the clinical context and aligned with current international classification systems.
Abstract
Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease classification systems and laboratory reporting practices have significantly evolved. These developments necessitate a framework to support contemporary BM evaluation and reporting. This document, prepared by an international ICSH Working Party, provides updated guidance on the examination and reporting of BM specimens and is an extension and refinement of the 2008 ICSH guidelines. It outlines the appropriate application and integration of key diagnostic modalities, including morphological assessment of BM aspirate and trephine biopsy specimens, immunophenotypic analysis by flow cytometry and immunohistochemistry and molecular genetic testing. Central to this guidance is the principle of integrated reporting, whereby findings from all diagnostic modalities are synthesized within the clinical context and aligned with current international classification systems. The ICSH acknowledges the emergence of automated digital microscopy, computational decision support tools, and other technological innovations in BM analysis. These developments hold considerable promise, but whilst many remain under evaluation, specific guidance regarding their routine clinical implementation is beyond the scope of this document.
Central nervous system (CNS) involvement in hematolymphoid malignancies poses a diagnostic challenge and is associated with poor prognosis. Flow cytometry (FCM) has emerged as a sensitive diagnostic tool for detecting malignant cells in cerebrospinal fluid (CSF).
The objective of this study was to evaluate...
Pankaj Tripathi, Preeti Tripathi, Sanjeev Khera et al.· Journal of Marine Medical So...· 0 citations
Digital morphology can improve standardization, image traceability, remote consultation, education, proficiency testing, quality assurance, and selected aspects of laboratory workflow.
G. Zini· Clinical Chemistry and Labor...· 0 citations
Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm defined by the World Health Organization (WHO) by persistent peripheral blood monocytosis, dysplastic hematopoiesis, and a heterogeneous clinical course. In routine practice, CMML may initially present with non-specific cytopenias and subtle dysgra...
R. Jácomo, C. Araújo, B. Barreto et al.· Clinical Chemistry· 0 citations
This review evaluates current clinical applications, limitations, and implementation challenges of flow cytometry for hematopoietic disorders in clinical laboratories. Flow cytometry is an essential tool for detecting and monitoring various diseases, such as minimal residual disease (MRD). With substantial techno...
BACKGROUND
Myelofibrosis (MF) is a myeloid bone marrow malignancy with a progressive clinical course marked by disease-related symptoms, splenomegaly, cytopenias, thrombosis/hemorrhage, and a risk for blast phase transformation. Treatment recommendations are based on the burden of symptoms, prognosis of the disease, an...
B. Stein, Maya Abdallah, Gregory A. Abel et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.